Additional file 8 of Candidate methylation sites associated with endocrine therapy resistance in ER+/HER2- breast cancer

Additional file 8. Survival analysis using risk score. Results of survival analysis of the multi-locus signature using the risk score corrected for selected clinical variables in ER+/HER2-, TAM and AI cohorts.

补充材料8：基于风险评分的生存分析。本部分呈现了在雌激素受体阳性/人表皮生长因子受体2阴性（ER+/HER2-）、他莫昔芬（TAM）与芳香化酶抑制剂（AI）队列中，针对多位点特征，使用经选定临床变量校正后的风险评分进行生存分析所得的结果。